Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

355 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Bendamustine with rituximab, etoposide and carboplatin (T(R)EC) in relapsed or refractory aggressive lymphoma: a prospective multicentre phase 1/2 clinical trial.
Budde LE, Wu D, Martin DB, Philip M, Shustov AR, Smith SD, Gooley TA, Chen TL, Libby EN, Chen EY, Kojouri K, Langerak A, Roden JE, Press OW, Gopal AK. Budde LE, et al. Among authors: philip m. Br J Haematol. 2018 Nov;183(4):601-607. doi: 10.1111/bjh.15585. Epub 2018 Sep 14. Br J Haematol. 2018. PMID: 30596402 Free PMC article. Clinical Trial.
Autologous transplant for relapsed follicular lymphoma: impact of pre-transplant rituximab sensitivity.
Phipps C, Gopal AK, Storer BE, Cassaday RD, Press OW, Till BG, Pagel JM, Palanca-Wessels MC, Philip M, Bensinger WI, Holmberg LA, Shustov AR, Green DJ, Chauncey T, Maloney DG, Libby EN 3rd. Phipps C, et al. Among authors: philip m. Leuk Lymphoma. 2015 Jan;56(1):92-6. doi: 10.3109/10428194.2014.911866. Epub 2014 Jun 17. Leuk Lymphoma. 2015. PMID: 24707941 Free PMC article.
High-dose CD20-targeted radioimmunotherapy-based autologous transplantation improves outcomes for persistent mantle cell lymphoma.
Cassaday RD, Stevenson PA, Gooley TA, Chauncey TR, Pagel JM, Rajendran J, Till BG, Philip M, Orozco JJ, Bensinger WI, Holmberg LA, Shustov AR, Green DJ, Smith SD, Libby EN, Maloney DG, Press OW, Gopal AK. Cassaday RD, et al. Among authors: philip m. Br J Haematol. 2015 Dec;171(5):788-97. doi: 10.1111/bjh.13773. Epub 2015 Oct 12. Br J Haematol. 2015. PMID: 26455717 Free PMC article.
Dose-dense brentuximab vedotin plus ifosfamide, carboplatin, and etoposide for second-line treatment of relapsed or refractory classical Hodgkin lymphoma: a single centre, phase 1/2 study.
Lynch RC, Cassaday RD, Smith SD, Fromm JR, Cowan AJ, Warren EH, Shadman MS, Shustov A, Till BG, Ujjani CS, Libby EN 3rd, Philip M, Coye H, Martino CN, Bhark SL, Morris K, Rasmussen H, Behnia S, Voutsinas J, Gopal AK. Lynch RC, et al. Among authors: philip m. Lancet Haematol. 2021 Aug;8(8):e562-e571. doi: 10.1016/S2352-3026(21)00170-8. Lancet Haematol. 2021. PMID: 34329577 Free PMC article. Clinical Trial.
Maintenance rituximab after autologous stem cell transplantation in patients with mantle cell lymphoma.
Graf SA, Stevenson PA, Holmberg LA, Till BG, Press OW, Chauncey TR, Smith SD, Philip M, Orozco JJ, Shustov AR, Green DJ, Libby EN 3rd, Bensinger WI, Pagel JM, Maloney DG, Zhou Y, Cassaday RD, Gopal AK. Graf SA, et al. Among authors: philip m. Ann Oncol. 2015 Nov;26(11):2323-8. doi: 10.1093/annonc/mdv364. Epub 2015 Sep 7. Ann Oncol. 2015. PMID: 26347113 Free PMC article.
Specific features identify patients with relapsed or refractory mantle cell lymphoma benefitting from autologous hematopoietic cell transplantation.
Cassaday RD, Guthrie KA, Budde EL, Thompson L, Till BG, Press OW, Chauncey TR, Pagel JM, Petersdorf SH, Palanca-Wessels MC, Philip M, Bensinger WI, Holmberg LA, Shustov A, Green DJ, Libby EN, Maloney DG, Gopal AK. Cassaday RD, et al. Among authors: philip m. Biol Blood Marrow Transplant. 2013 Sep;19(9):1403-6. doi: 10.1016/j.bbmt.2013.07.005. Epub 2013 Jul 17. Biol Blood Marrow Transplant. 2013. PMID: 23871782 Free PMC article.
Brentuximab vedotin administered to platinum-refractory, transplant-naïve Hodgkin lymphoma patients can increase the proportion achieving FDG PET negative status.
Onishi M, Graf SA, Holmberg L, Behnia S, Shustov AR, Schiavo K, Philip M, Libby EN, Cassaday RD, Pagel JM, Roden JE, Maloney DG, Green DJ, Till BG, Press OW, Smith SD, Gopal AK. Onishi M, et al. Among authors: philip m. Hematol Oncol. 2015 Dec;33(4):187-91. doi: 10.1002/hon.2166. Epub 2014 Sep 18. Hematol Oncol. 2015. PMID: 25236531 Free PMC article.
Pretransplantation Minimal Residual Disease Predicts Survival in Patients with Mantle Cell Lymphoma Undergoing Autologous Stem Cell Transplantation in Complete Remission.
Cowan AJ, Stevenson PA, Cassaday RD, Graf SA, Fromm JR, Wu D, Holmberg LA, Till BG, Chauncey TR, Smith SD, Philip M, Orozco JJ, Shustov AR, Green DJ, Libby EN 3rd, Bensinger WI, Shadman M, Maloney DG, Press OW, Gopal AK. Cowan AJ, et al. Among authors: philip m. Biol Blood Marrow Transplant. 2016 Feb;22(2):380-385. doi: 10.1016/j.bbmt.2015.08.035. Epub 2015 Sep 5. Biol Blood Marrow Transplant. 2016. PMID: 26348890 Free PMC article.
Tumor-Specific T Cell Dysfunction Is a Dynamic Antigen-Driven Differentiation Program Initiated Early during Tumorigenesis.
Schietinger A, Philip M, Krisnawan VE, Chiu EY, Delrow JJ, Basom RS, Lauer P, Brockstedt DG, Knoblaugh SE, Hämmerling GJ, Schell TD, Garbi N, Greenberg PD. Schietinger A, et al. Among authors: philip m. Immunity. 2016 Aug 16;45(2):389-401. doi: 10.1016/j.immuni.2016.07.011. Epub 2016 Aug 9. Immunity. 2016. PMID: 27521269 Free PMC article.
355 results